Granata Bio deepens U.S. fertility play with Gedeon Richter partnership
The two firms will align on commercial and development fronts
Biopharma Granata Bio, a startup focused on invigorating the $3.6B global infertility medication market, has announced a strategic partnership with Hungarian women’s health pharma giant Gedeon Richter.
The deal, which includes a significant equity investment and board representation, demonstrates Richter’s ambitions in the American market and Granata’s rapid growth trajectory - particularly following its recent acquisition of Oviva Therapeutics.
The collaboration will see the two firms align on commercial and developmental fronts, notably through the co-development of BEMFOLA® - Richter’s recombinant follicle stimulating hormone (FSH) - for the U.S. market. The companies have also inked a royalty agreement for Granata’s human menopausal gonadotropin (hMG) programme, tightening strategic interests across the fertility spectrum.
"We're proud to partner with Gedeon Richter, an organization whose global footprint and manufacturing excellence perfectly complement Granata Bio's strengths in the U.S. market.
“This collaboration brings together the best of both companies: deep therapeutic expertise, operational agility, and a shared commitment to improving access to fertility care," said Evan Sussman, CEO and co-founder of Granata Bio.
The agreement also brings a representative from Richter onto Granata’s board.
For Richter, the partnership complements its stated ambitions to expand its women’s health portfolio beyond Europe. The Budapest-headquartered company operates one of Central Europe’s largest R&D hubs and has long maintained a strong presence in global reproductive medicine markets.
Stephen Medeiros, Granata’s Chief Operating Officer, highlighted the clinical implications:
“FSH is the most prescribed gonadotropin by volume and represents a cornerstone of ovarian stimulation treatment. The addition of BEMFOLA® to our pipeline significantly strengthens our portfolio, providing coverage across all major IVF product categories. Together, these assets position us to better support the evolving needs of patients and providers in the U.S. fertility landscape.”
Key player in fertility sector
Granata, founded in 2018, identifies strategic medications used in IVF outside of the US for clinical development and commercialisation in North America. It has emerged as a fast-moving player in the fertility sector, aiming to fill clinical gaps with a focus on therapeutic innovation and accessibility - where it has stated ambitions to reduce the cost of IVF medications for patients.
Its acquisition of Oviva Therapeutics just last month also brought it a first-in-class programme aimed at preserving ovarian function and extending reproductive healthspan — perhaps a signal of the company's broader intent to lead not just in fertility, but in the longer arc of women’s health.
In January of this year Granata also secured a $15million Series A+ to further its fertility medication pipeline. That round was supported by investors including Gedeon Richter. Granata has now raised over $30 million to date.
Both Granata and Richter have signalled that further announcements on product timelines and regulatory milestones will follow.